Home LiteratureArticle Details
PMID: 18971141 Published · ppublish English

Occult fallopian tube cancer in a patient with BRCA1 breast cancer.

Journal of minimally invasive gynecology ·Vol. 15 ·No. 6 ·2009-02-19

Brown John V, Epstein Howard D, Mattison Julie N, Micha John P, Rettenmaier Mark A, Goldstein Bram H

Abstract

Primary fallopian tube cancer is very rare form of ovarian cancer. However, despite the infrequent incidence, emerging evidence suggests that patients who have a deleterious mutation of BRCA1 or -2 mutation may be more vulnerable to developing this disease. A patient with breast carcinoma was initially treated for her disease in 1994. She had a new primary lesion on the contralateral side in 2001 and was eventually identified with a positive BRCA1 germline mutation in 2007. The patient subsequently underwent a laparoscopic-assisted vaginal hysterectomy and bilateral salpingo-oophorectomy surgery performed by her gynecologist. Final pathology revealed occult stage IIC fallopian tube cancer with bilateral ovarian serosal involvement. Consequently, the patient was referred to gynecologic oncology and underwent a pelvic and paraaortic lymphadenectomy and laparoscopic omentectomy, followed by chemotherapy. Although fallopian tube cancer is rare, women who are positive for the BRCA mutation are at greater risk for developing this disease. Therefore, physicians should consider the associated risk factors and perform comprehensive risk-reducing surgery and staging when treating these patients.

Article Info
Journal
Journal of minimally invasive gynecology
Abbr.
J Minim Invasive Gynecol
Published
2009-02-19
Indexed
2008-10-30
Updated
2015-11-19
Language
English
Country/Region
United States
NLM ID
101235322
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com